URGN
UroGen Pharma LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$987.28M
P/E Ratio
—
EPS
$-3.19
Beta
1.44
52W High
$30.00
52W Low
$3.42
50-Day MA
$19.65
200-Day MA
$19.78
Dividend Yield
—
Profit Margin
-139.80%
Forward P/E
—
PEG Ratio
0.00
About UroGen Pharma Ltd
UroGen Pharma Ltd (URGN) is a biotechnology company focused on pioneering therapies for urological conditions, particularly urothelial carcinoma and bladder cancer. Utilizing its proprietary reverse thermal gel platform, UroGen facilitates sustained local drug delivery, enhancing therapeutic effectiveness while minimizing systemic exposure. The company boasts a robust clinical pipeline aimed at addressing critical unmet needs within urology, positioning itself as a leader in the sector with the potential to significantly improve patient outcomes.
Fundamentals
| Revenue (TTM) | $109.79M |
| Gross Profit (TTM) | $97.34M |
| EBITDA | $-124.56M |
| Operating Margin | -50.50% |
| Return on Equity | -1481.00% |
| Return on Assets | -32.10% |
| Revenue/Share (TTM) | $2.28 |
| Book Value | $-2.18 |
| Price-to-Book | 19.27 |
| Price-to-Sales (TTM) | 9.56 |
| EV/Revenue | 9.64 |
| EV/EBITDA | -2.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 54.00% |
| Shares Outstanding | $48.68M |
| Float | $38.66M |
| % Insiders | 3.75% |
| % Institutions | 98.31% |
Historical Volatility
HV 10-Day
73.18%
HV 20-Day
60.93%
HV 30-Day
69.60%
HV 60-Day
60.59%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($36.11 target)
1
Strong Buy6
Buy1
HoldData last updated: 4/14/2026